© 2023 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
February 01, 2023
A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.
January 23, 2023
Other adverse outcomes were not linked to histological inflammation, according to results of a Swedish study.
January 13, 2023
Cobitolimod from InDex, a Swedish company, and obefazimod, from Abivax, a French company, could be first-in-class medications for ulcerative colitis.
January 09, 2023
Stomach acid interferes with the effectiveness of probiotics taken as pills. Researchers are bioengineering probiotics in hopes of getting around that problem.